IP Verse

Zentiva vs. Sanofi Mature - UPC_CFI_503/2024

The UPC Case UPC_CFI_503/2024 was filed on 02 Sep, 2024 by the plaintiff Zentiva, Zentiva France, Zentiva Pharma against the defendant Sanofi Mature.

Case Details

    Case Number:

    UPC_CFI_503/2024

    Patent Number:

    EP2493466

    Filing Date:

    02 Sep, 2024

    Proceeding Type:

    Counter Claim For Revocation

    Case Phase:

    Interim Phase

    Plaintiffs:

    • Zentiva
    • Zentiva France
    • Zentiva Pharma

    Plaintiff Representatives:

    • Anja LUNZE

    Defendants:

    • Sanofi Mature

    Defendant Representatives:

    • Frédéric CHEVALLIER

    Judges:

    • Alima Zana
    • Matthias Zigann
    • Tobias Pichlmaier

Case Decision

Decision pending - set alert to receive updates

Docket Entries

The docket entries provide a comprehensive overview of all filings, motions, orders, and other significant actions taken in the case.

DateTitleLink
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 10, 2025Acknowledgement Of Change Of A Representative-
Jul 8, 2025Formal Checks Notification Of Positive Outcome-
Jul 8, 2025Exhibit Tw D 17 Signed-
Jul 8, 2025Exhibit Tw D 16 Signed-
Jul 8, 2025Exhibit Tw D 15 Signed-
Jul 8, 2025Exhibit Tw D 14 Signed-
Jul 8, 2025Exhibit Dfmp D115 Signed-
Jul 8, 2025Exhibit Dfmp D114 Signed-
Jul 8, 2025Application Rop293 Receipt-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Sanovi VS. Zentiva Zentiva Rejoinder Infringement Reply Counterclaim Signed-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
May 8, 2025Outcome Of The Order-
May 8, 2025Final Order
Apr 11, 2025Receipt-
Apr 9, 2025Exhibit Tw D9 Signed-
Apr 9, 2025Exhibit Tw D12B 373 740 Signed-
Apr 9, 2025Exhibit Tw D12A 1 372 Signed-
Apr 9, 2025Exhibit Tw D11 Signed-
Apr 9, 2025Exhibit Tw D10 Signed-
Apr 9, 202504 09 Sanofi V Zentiva Zentiva Reply To Sanofi Comments No 2 R. 105 Signed-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 24, 2025Headnote And Keywords-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 30, 2024Zustellnachweis-
Sep 30, 2024Notification Of Service-
Sep 25, 2024Acknowledgement Of Access To Case-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Document From Epo-
Sep 4, 2024Panel Appointment-
Sep 4, 2024Letter For Service-
Sep 4, 2024Formal Checks Notification Of Positive Outcome-
Sep 4, 2024Epo Request For Case Pending-
Sep 4, 2024Acknowledgement Of Lodging-
Sep 2, 2024Tw D8 De Leaflet Cabazitaxel-
Sep 2, 2024Tw D7 De Smpc Cabazitaxel-
Sep 2, 2024Tw D6 Fr Leaflet Cabazitaxel-
Sep 2, 2024Tw D5 Fr Smpc Cabazitaxel-
Sep 2, 2024Tw D4 Ansm Cabazitaxel-
Sep 2, 2024Tw D3 Report Eu Commission-
Sep 2, 2024Tw D2 Medicines For Europe-
Sep 2, 2024Dfmp P7 Priority Document US61 389,969-
Sep 2, 2024Dfmp P6 Priority Document US61 383933-
Sep 2, 2024Dfmp P5 Priority Document US61 369929-
Sep 2, 2024Dfmp P4 Priority Document US61 355888-
Sep 2, 2024Dfmp P3 Priority Document US61 355834-
Sep 2, 2024Dfmp P2 Priority Document US61 293903-
Sep 2, 2024Dfmp P1 Priority Document US61 256160-
Sep 2, 2024Dfmp D9 Galletti Et Al.-
Sep 2, 2024Dfmp D91 Bissery Et Al.-
Sep 2, 2024Dfmp D90 Goetz Et Al.-
Sep 2, 2024Dfmp D7 Beardsley Et Al.-
Sep 2, 2024Dfmp D72 Scher Et Al.-
Sep 2, 2024Dfmp D4 Mita Et Al.-
Sep 2, 2024Dfmp D3B Further Blog Post By Dr. Mirtsching July 6-
Sep 2, 2024Dfmp D3A Blog Post By Dr. Barry Mirtsching 12 October-
Sep 2, 2024Dfmp D38 Sanofi Press Release September 17-
Sep 2, 2024Dfmp D37 Winquist Et Al.-
Sep 2, 2024Dfmp D35 Leaflet Aventis Oncology-
Sep 2, 2024Dfmp D2 National Horizon Scanning Centre-
Sep 2, 2024Dfmp D29 Tannock Et Al.-
Sep 2, 2024Dfmp D26 Attard Et Al.-
Sep 2, 2024Dfmp D25 Correspondence Lancet 2011 377 121 122-
Sep 2, 2024Dfmp D21 Ema Assessment Report For Jevtana (Cabazitaxel) January 20-
Sep 2, 2024Dfmp D1 Sanofi Aventis Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone-
Sep 2, 2024Dfmp D18 Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man-
Sep 2, 2024Dfmp D15 De Bono Et Al.-
Sep 2, 2024Dfmp D14 Fda Label For Docetaxel (Taxotere)-
Sep 2, 2024Dfmp D13 Pivot Et Al.-
Sep 2, 2024Dfmp D11 Les Echos 22 Dec-
Sep 2, 2024Dfmp D113 Us Code Of Federal Regulations Title 21 Chapter I Part 314-
Sep 2, 2024Dfmp D112 Excerpt From The Online National Cancer Institute S Drug Dictionary Re. Cabazitaxel-
Sep 2, 2024Dfmp D111 Inn Publication-
Sep 2, 2024Dfmp D110 Consolidated List Of Documents Epo-
Sep 2, 2024Dfmp D10 Sanofi Aventis Press Release 21 December-
Sep 2, 2024Dfmp D109 Albarqouni-
Sep 2, 2024Dfmp D108 Barraclough And Davis-
Sep 2, 2024Dfmp D105 Sava Et Al.-
Sep 2, 2024Dfmp D104 Tannock Clin. Oncol. 1996-
Sep 2, 2024Dfmp D103 Fossa. Et Al.-
Sep 2, 2024Dfmp D102 Tannock Clin. Oncol. 1989-
Sep 2, 202409 02 Sanofi VS. Zentiva Statement Of Defence And Counterclaim For Revoc-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 10, 2025Acknowledgement Of Change Of A Representative-
Jul 8, 2025Formal Checks Notification Of Positive Outcome-
Jul 8, 2025Exhibit Tw D 17 Signed-
Jul 8, 2025Exhibit Tw D 16 Signed-
Jul 8, 2025Exhibit Tw D 15 Signed-
Jul 8, 2025Exhibit Tw D 14 Signed-
Jul 8, 2025Exhibit Dfmp D115 Signed-
Jul 8, 2025Exhibit Dfmp D114 Signed-
Jul 8, 2025Application Rop293 Receipt-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Sanovi VS. Zentiva Zentiva Rejoinder Infringement Reply Counterclaim Signed-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
May 8, 2025Outcome Of The Order-
May 8, 2025Final Order
Apr 11, 2025Receipt-
Apr 9, 2025Exhibit Tw D9 Signed-
Apr 9, 2025Exhibit Tw D12B 373 740 Signed-
Apr 9, 2025Exhibit Tw D12A 1 372 Signed-
Apr 9, 2025Exhibit Tw D11 Signed-
Apr 9, 2025Exhibit Tw D10 Signed-
Apr 9, 202504 09 Sanofi V Zentiva Zentiva Reply To Sanofi Comments No 2 R. 105 Signed-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 24, 2025Headnote And Keywords-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 30, 2024Zustellnachweis-
Sep 30, 2024Notification Of Service-
Sep 25, 2024Acknowledgement Of Access To Case-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Document From Epo-
Sep 4, 2024Panel Appointment-
Sep 4, 2024Letter For Service-
Sep 4, 2024Formal Checks Notification Of Positive Outcome-
Sep 4, 2024Epo Request For Case Pending-
Sep 4, 2024Acknowledgement Of Lodging-
Sep 2, 2024Tw D8 De Leaflet Cabazitaxel-
Sep 2, 2024Tw D7 De Smpc Cabazitaxel-
Sep 2, 2024Tw D6 Fr Leaflet Cabazitaxel-
Sep 2, 2024Tw D5 Fr Smpc Cabazitaxel-
Sep 2, 2024Tw D4 Ansm Cabazitaxel-
Sep 2, 2024Tw D3 Report Eu Commission-
Sep 2, 2024Tw D2 Medicines For Europe-
Sep 2, 2024Dfmp P7 Priority Document US61 389,969-
Sep 2, 2024Dfmp P6 Priority Document US61 383933-
Sep 2, 2024Dfmp P5 Priority Document US61 369929-
Sep 2, 2024Dfmp P4 Priority Document US61 355888-
Sep 2, 2024Dfmp P3 Priority Document US61 355834-
Sep 2, 2024Dfmp P2 Priority Document US61 293903-
Sep 2, 2024Dfmp P1 Priority Document US61 256160-
Sep 2, 2024Dfmp D9 Galletti Et Al.-
Sep 2, 2024Dfmp D91 Bissery Et Al.-
Sep 2, 2024Dfmp D90 Goetz Et Al.-
Sep 2, 2024Dfmp D7 Beardsley Et Al.-
Sep 2, 2024Dfmp D72 Scher Et Al.-
Sep 2, 2024Dfmp D4 Mita Et Al.-
Sep 2, 2024Dfmp D3B Further Blog Post By Dr. Mirtsching July 6-
Sep 2, 2024Dfmp D3A Blog Post By Dr. Barry Mirtsching 12 October-
Sep 2, 2024Dfmp D38 Sanofi Press Release September 17-
Sep 2, 2024Dfmp D37 Winquist Et Al.-
Sep 2, 2024Dfmp D35 Leaflet Aventis Oncology-
Sep 2, 2024Dfmp D2 National Horizon Scanning Centre-
Sep 2, 2024Dfmp D29 Tannock Et Al.-
Sep 2, 2024Dfmp D26 Attard Et Al.-
Sep 2, 2024Dfmp D25 Correspondence Lancet 2011 377 121 122-
Sep 2, 2024Dfmp D21 Ema Assessment Report For Jevtana (Cabazitaxel) January 20-
Sep 2, 2024Dfmp D1 Sanofi Aventis Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone-
Sep 2, 2024Dfmp D18 Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man-
Sep 2, 2024Dfmp D15 De Bono Et Al.-
Sep 2, 2024Dfmp D14 Fda Label For Docetaxel (Taxotere)-
Sep 2, 2024Dfmp D13 Pivot Et Al.-
Sep 2, 2024Dfmp D11 Les Echos 22 Dec-
Sep 2, 2024Dfmp D113 Us Code Of Federal Regulations Title 21 Chapter I Part 314-
Sep 2, 2024Dfmp D112 Excerpt From The Online National Cancer Institute S Drug Dictionary Re. Cabazitaxel-
Sep 2, 2024Dfmp D111 Inn Publication-
Sep 2, 2024Dfmp D110 Consolidated List Of Documents Epo-
Sep 2, 2024Dfmp D10 Sanofi Aventis Press Release 21 December-
Sep 2, 2024Dfmp D109 Albarqouni-
Sep 2, 2024Dfmp D108 Barraclough And Davis-
Sep 2, 2024Dfmp D105 Sava Et Al.-
Sep 2, 2024Dfmp D104 Tannock Clin. Oncol. 1996-
Sep 2, 2024Dfmp D103 Fossa. Et Al.-
Sep 2, 2024Dfmp D102 Tannock Clin. Oncol. 1989-
Sep 2, 202409 02 Sanofi VS. Zentiva Statement Of Defence And Counterclaim For Revoc-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 10, 2025Acknowledgement Of Change Of A Representative-
Jul 8, 2025Formal Checks Notification Of Positive Outcome-
Jul 8, 2025Exhibit Tw D 17 Signed-
Jul 8, 2025Exhibit Tw D 16 Signed-
Jul 8, 2025Exhibit Tw D 15 Signed-
Jul 8, 2025Exhibit Tw D 14 Signed-
Jul 8, 2025Exhibit Dfmp D115 Signed-
Jul 8, 2025Exhibit Dfmp D114 Signed-
Jul 8, 2025Application Rop293 Receipt-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Sanovi VS. Zentiva Zentiva Rejoinder Infringement Reply Counterclaim Signed-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
May 8, 2025Outcome Of The Order-
May 8, 2025Final Order
Apr 11, 2025Receipt-
Apr 9, 2025Exhibit Tw D9 Signed-
Apr 9, 2025Exhibit Tw D12B 373 740 Signed-
Apr 9, 2025Exhibit Tw D12A 1 372 Signed-
Apr 9, 2025Exhibit Tw D11 Signed-
Apr 9, 2025Exhibit Tw D10 Signed-
Apr 9, 202504 09 Sanofi V Zentiva Zentiva Reply To Sanofi Comments No 2 R. 105 Signed-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 24, 2025Headnote And Keywords-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 30, 2024Zustellnachweis-
Sep 30, 2024Notification Of Service-
Sep 25, 2024Acknowledgement Of Access To Case-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Document From Epo-
Sep 4, 2024Panel Appointment-
Sep 4, 2024Letter For Service-
Sep 4, 2024Formal Checks Notification Of Positive Outcome-
Sep 4, 2024Epo Request For Case Pending-
Sep 4, 2024Acknowledgement Of Lodging-
Sep 2, 2024Tw D8 De Leaflet Cabazitaxel-
Sep 2, 2024Tw D7 De Smpc Cabazitaxel-
Sep 2, 2024Tw D6 Fr Leaflet Cabazitaxel-
Sep 2, 2024Tw D5 Fr Smpc Cabazitaxel-
Sep 2, 2024Tw D4 Ansm Cabazitaxel-
Sep 2, 2024Tw D3 Report Eu Commission-
Sep 2, 2024Tw D2 Medicines For Europe-
Sep 2, 2024Dfmp P7 Priority Document US61 389,969-
Sep 2, 2024Dfmp P6 Priority Document US61 383933-
Sep 2, 2024Dfmp P5 Priority Document US61 369929-
Sep 2, 2024Dfmp P4 Priority Document US61 355888-
Sep 2, 2024Dfmp P3 Priority Document US61 355834-
Sep 2, 2024Dfmp P2 Priority Document US61 293903-
Sep 2, 2024Dfmp P1 Priority Document US61 256160-
Sep 2, 2024Dfmp D9 Galletti Et Al.-
Sep 2, 2024Dfmp D91 Bissery Et Al.-
Sep 2, 2024Dfmp D90 Goetz Et Al.-
Sep 2, 2024Dfmp D7 Beardsley Et Al.-
Sep 2, 2024Dfmp D72 Scher Et Al.-
Sep 2, 2024Dfmp D4 Mita Et Al.-
Sep 2, 2024Dfmp D3B Further Blog Post By Dr. Mirtsching July 6-
Sep 2, 2024Dfmp D3A Blog Post By Dr. Barry Mirtsching 12 October-
Sep 2, 2024Dfmp D38 Sanofi Press Release September 17-
Sep 2, 2024Dfmp D37 Winquist Et Al.-
Sep 2, 2024Dfmp D35 Leaflet Aventis Oncology-
Sep 2, 2024Dfmp D2 National Horizon Scanning Centre-
Sep 2, 2024Dfmp D29 Tannock Et Al.-
Sep 2, 2024Dfmp D26 Attard Et Al.-
Sep 2, 2024Dfmp D25 Correspondence Lancet 2011 377 121 122-
Sep 2, 2024Dfmp D21 Ema Assessment Report For Jevtana (Cabazitaxel) January 20-
Sep 2, 2024Dfmp D1 Sanofi Aventis Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone-
Sep 2, 2024Dfmp D18 Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man-
Sep 2, 2024Dfmp D15 De Bono Et Al.-
Sep 2, 2024Dfmp D14 Fda Label For Docetaxel (Taxotere)-
Sep 2, 2024Dfmp D13 Pivot Et Al.-
Sep 2, 2024Dfmp D11 Les Echos 22 Dec-
Sep 2, 2024Dfmp D113 Us Code Of Federal Regulations Title 21 Chapter I Part 314-
Sep 2, 2024Dfmp D112 Excerpt From The Online National Cancer Institute S Drug Dictionary Re. Cabazitaxel-
Sep 2, 2024Dfmp D111 Inn Publication-
Sep 2, 2024Dfmp D110 Consolidated List Of Documents Epo-
Sep 2, 2024Dfmp D10 Sanofi Aventis Press Release 21 December-
Sep 2, 2024Dfmp D109 Albarqouni-
Sep 2, 2024Dfmp D108 Barraclough And Davis-
Sep 2, 2024Dfmp D105 Sava Et Al.-
Sep 2, 2024Dfmp D104 Tannock Clin. Oncol. 1996-
Sep 2, 2024Dfmp D103 Fossa. Et Al.-
Sep 2, 2024Dfmp D102 Tannock Clin. Oncol. 1989-
Sep 2, 202409 02 Sanofi VS. Zentiva Statement Of Defence And Counterclaim For Revoc-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 10, 2025Acknowledgement Of Change Of A Representative-
Jul 8, 2025Formal Checks Notification Of Positive Outcome-
Jul 8, 2025Exhibit Tw D 17 Signed-
Jul 8, 2025Exhibit Tw D 16 Signed-
Jul 8, 2025Exhibit Tw D 15 Signed-
Jul 8, 2025Exhibit Tw D 14 Signed-
Jul 8, 2025Exhibit Dfmp D115 Signed-
Jul 8, 2025Exhibit Dfmp D114 Signed-
Jul 8, 2025Application Rop293 Receipt-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Sanovi VS. Zentiva Zentiva Rejoinder Infringement Reply Counterclaim Signed-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
May 8, 2025Outcome Of The Order-
May 8, 2025Final Order
Apr 11, 2025Receipt-
Apr 9, 2025Exhibit Tw D9 Signed-
Apr 9, 2025Exhibit Tw D12B 373 740 Signed-
Apr 9, 2025Exhibit Tw D12A 1 372 Signed-
Apr 9, 2025Exhibit Tw D11 Signed-
Apr 9, 2025Exhibit Tw D10 Signed-
Apr 9, 202504 09 Sanofi V Zentiva Zentiva Reply To Sanofi Comments No 2 R. 105 Signed-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 24, 2025Headnote And Keywords-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 30, 2024Zustellnachweis-
Sep 30, 2024Notification Of Service-
Sep 25, 2024Acknowledgement Of Access To Case-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Document From Epo-
Sep 4, 2024Panel Appointment-
Sep 4, 2024Letter For Service-
Sep 4, 2024Formal Checks Notification Of Positive Outcome-
Sep 4, 2024Epo Request For Case Pending-
Sep 4, 2024Acknowledgement Of Lodging-
Sep 2, 2024Tw D8 De Leaflet Cabazitaxel-
Sep 2, 2024Tw D7 De Smpc Cabazitaxel-
Sep 2, 2024Tw D6 Fr Leaflet Cabazitaxel-
Sep 2, 2024Tw D5 Fr Smpc Cabazitaxel-
Sep 2, 2024Tw D4 Ansm Cabazitaxel-
Sep 2, 2024Tw D3 Report Eu Commission-
Sep 2, 2024Tw D2 Medicines For Europe-
Sep 2, 2024Dfmp P7 Priority Document US61 389,969-
Sep 2, 2024Dfmp P6 Priority Document US61 383933-
Sep 2, 2024Dfmp P5 Priority Document US61 369929-
Sep 2, 2024Dfmp P4 Priority Document US61 355888-
Sep 2, 2024Dfmp P3 Priority Document US61 355834-
Sep 2, 2024Dfmp P2 Priority Document US61 293903-
Sep 2, 2024Dfmp P1 Priority Document US61 256160-
Sep 2, 2024Dfmp D9 Galletti Et Al.-
Sep 2, 2024Dfmp D91 Bissery Et Al.-
Sep 2, 2024Dfmp D90 Goetz Et Al.-
Sep 2, 2024Dfmp D7 Beardsley Et Al.-
Sep 2, 2024Dfmp D72 Scher Et Al.-
Sep 2, 2024Dfmp D4 Mita Et Al.-
Sep 2, 2024Dfmp D3B Further Blog Post By Dr. Mirtsching July 6-
Sep 2, 2024Dfmp D3A Blog Post By Dr. Barry Mirtsching 12 October-
Sep 2, 2024Dfmp D38 Sanofi Press Release September 17-
Sep 2, 2024Dfmp D37 Winquist Et Al.-
Sep 2, 2024Dfmp D35 Leaflet Aventis Oncology-
Sep 2, 2024Dfmp D2 National Horizon Scanning Centre-
Sep 2, 2024Dfmp D29 Tannock Et Al.-
Sep 2, 2024Dfmp D26 Attard Et Al.-
Sep 2, 2024Dfmp D25 Correspondence Lancet 2011 377 121 122-
Sep 2, 2024Dfmp D21 Ema Assessment Report For Jevtana (Cabazitaxel) January 20-
Sep 2, 2024Dfmp D1 Sanofi Aventis Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone-
Sep 2, 2024Dfmp D18 Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man-
Sep 2, 2024Dfmp D15 De Bono Et Al.-
Sep 2, 2024Dfmp D14 Fda Label For Docetaxel (Taxotere)-
Sep 2, 2024Dfmp D13 Pivot Et Al.-
Sep 2, 2024Dfmp D11 Les Echos 22 Dec-
Sep 2, 2024Dfmp D113 Us Code Of Federal Regulations Title 21 Chapter I Part 314-
Sep 2, 2024Dfmp D112 Excerpt From The Online National Cancer Institute S Drug Dictionary Re. Cabazitaxel-
Sep 2, 2024Dfmp D111 Inn Publication-
Sep 2, 2024Dfmp D110 Consolidated List Of Documents Epo-
Sep 2, 2024Dfmp D10 Sanofi Aventis Press Release 21 December-
Sep 2, 2024Dfmp D109 Albarqouni-
Sep 2, 2024Dfmp D108 Barraclough And Davis-
Sep 2, 2024Dfmp D105 Sava Et Al.-
Sep 2, 2024Dfmp D104 Tannock Clin. Oncol. 1996-
Sep 2, 2024Dfmp D103 Fossa. Et Al.-
Sep 2, 2024Dfmp D102 Tannock Clin. Oncol. 1989-
Sep 2, 202409 02 Sanofi VS. Zentiva Statement Of Defence And Counterclaim For Revoc-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 10, 2025Acknowledgement Of Change Of A Representative-
Jul 8, 2025Formal Checks Notification Of Positive Outcome-
Jul 8, 2025Exhibit Tw D 17 Signed-
Jul 8, 2025Exhibit Tw D 16 Signed-
Jul 8, 2025Exhibit Tw D 15 Signed-
Jul 8, 2025Exhibit Tw D 14 Signed-
Jul 8, 2025Exhibit Dfmp D115 Signed-
Jul 8, 2025Exhibit Dfmp D114 Signed-
Jul 8, 2025Application Rop293 Receipt-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Sanovi VS. Zentiva Zentiva Rejoinder Infringement Reply Counterclaim Signed-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
May 8, 2025Outcome Of The Order-
May 8, 2025Final Order
Apr 11, 2025Receipt-
Apr 9, 2025Exhibit Tw D9 Signed-
Apr 9, 2025Exhibit Tw D12B 373 740 Signed-
Apr 9, 2025Exhibit Tw D12A 1 372 Signed-
Apr 9, 2025Exhibit Tw D11 Signed-
Apr 9, 2025Exhibit Tw D10 Signed-
Apr 9, 202504 09 Sanofi V Zentiva Zentiva Reply To Sanofi Comments No 2 R. 105 Signed-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 24, 2025Headnote And Keywords-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 30, 2024Zustellnachweis-
Sep 30, 2024Notification Of Service-
Sep 25, 2024Acknowledgement Of Access To Case-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Document From Epo-
Sep 4, 2024Panel Appointment-
Sep 4, 2024Letter For Service-
Sep 4, 2024Formal Checks Notification Of Positive Outcome-
Sep 4, 2024Epo Request For Case Pending-
Sep 4, 2024Acknowledgement Of Lodging-
Sep 2, 2024Tw D8 De Leaflet Cabazitaxel-
Sep 2, 2024Tw D7 De Smpc Cabazitaxel-
Sep 2, 2024Tw D6 Fr Leaflet Cabazitaxel-
Sep 2, 2024Tw D5 Fr Smpc Cabazitaxel-
Sep 2, 2024Tw D4 Ansm Cabazitaxel-
Sep 2, 2024Tw D3 Report Eu Commission-
Sep 2, 2024Tw D2 Medicines For Europe-
Sep 2, 2024Dfmp P7 Priority Document US61 389,969-
Sep 2, 2024Dfmp P6 Priority Document US61 383933-
Sep 2, 2024Dfmp P5 Priority Document US61 369929-
Sep 2, 2024Dfmp P4 Priority Document US61 355888-
Sep 2, 2024Dfmp P3 Priority Document US61 355834-
Sep 2, 2024Dfmp P2 Priority Document US61 293903-
Sep 2, 2024Dfmp P1 Priority Document US61 256160-
Sep 2, 2024Dfmp D9 Galletti Et Al.-
Sep 2, 2024Dfmp D91 Bissery Et Al.-
Sep 2, 2024Dfmp D90 Goetz Et Al.-
Sep 2, 2024Dfmp D7 Beardsley Et Al.-
Sep 2, 2024Dfmp D72 Scher Et Al.-
Sep 2, 2024Dfmp D4 Mita Et Al.-
Sep 2, 2024Dfmp D3B Further Blog Post By Dr. Mirtsching July 6-
Sep 2, 2024Dfmp D3A Blog Post By Dr. Barry Mirtsching 12 October-
Sep 2, 2024Dfmp D38 Sanofi Press Release September 17-
Sep 2, 2024Dfmp D37 Winquist Et Al.-
Sep 2, 2024Dfmp D35 Leaflet Aventis Oncology-
Sep 2, 2024Dfmp D2 National Horizon Scanning Centre-
Sep 2, 2024Dfmp D29 Tannock Et Al.-
Sep 2, 2024Dfmp D26 Attard Et Al.-
Sep 2, 2024Dfmp D25 Correspondence Lancet 2011 377 121 122-
Sep 2, 2024Dfmp D21 Ema Assessment Report For Jevtana (Cabazitaxel) January 20-
Sep 2, 2024Dfmp D1 Sanofi Aventis Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone-
Sep 2, 2024Dfmp D18 Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man-
Sep 2, 2024Dfmp D15 De Bono Et Al.-
Sep 2, 2024Dfmp D14 Fda Label For Docetaxel (Taxotere)-
Sep 2, 2024Dfmp D13 Pivot Et Al.-
Sep 2, 2024Dfmp D11 Les Echos 22 Dec-
Sep 2, 2024Dfmp D113 Us Code Of Federal Regulations Title 21 Chapter I Part 314-
Sep 2, 2024Dfmp D112 Excerpt From The Online National Cancer Institute S Drug Dictionary Re. Cabazitaxel-
Sep 2, 2024Dfmp D111 Inn Publication-
Sep 2, 2024Dfmp D110 Consolidated List Of Documents Epo-
Sep 2, 2024Dfmp D10 Sanofi Aventis Press Release 21 December-
Sep 2, 2024Dfmp D109 Albarqouni-
Sep 2, 2024Dfmp D108 Barraclough And Davis-
Sep 2, 2024Dfmp D105 Sava Et Al.-
Sep 2, 2024Dfmp D104 Tannock Clin. Oncol. 1996-
Sep 2, 2024Dfmp D103 Fossa. Et Al.-
Sep 2, 2024Dfmp D102 Tannock Clin. Oncol. 1989-
Sep 2, 202409 02 Sanofi VS. Zentiva Statement Of Defence And Counterclaim For Revoc-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 10, 2025Acknowledgement Of Change Of A Representative-
Jul 8, 2025Formal Checks Notification Of Positive Outcome-
Jul 8, 2025Exhibit Tw D 17 Signed-
Jul 8, 2025Exhibit Tw D 16 Signed-
Jul 8, 2025Exhibit Tw D 15 Signed-
Jul 8, 2025Exhibit Tw D 14 Signed-
Jul 8, 2025Exhibit Dfmp D115 Signed-
Jul 8, 2025Exhibit Dfmp D114 Signed-
Jul 8, 2025Application Rop293 Receipt-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Sanovi VS. Zentiva Zentiva Rejoinder Infringement Reply Counterclaim Signed-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
May 8, 2025Outcome Of The Order-
May 8, 2025Final Order
Apr 11, 2025Receipt-
Apr 9, 2025Exhibit Tw D9 Signed-
Apr 9, 2025Exhibit Tw D12B 373 740 Signed-
Apr 9, 2025Exhibit Tw D12A 1 372 Signed-
Apr 9, 2025Exhibit Tw D11 Signed-
Apr 9, 2025Exhibit Tw D10 Signed-
Apr 9, 202504 09 Sanofi V Zentiva Zentiva Reply To Sanofi Comments No 2 R. 105 Signed-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 24, 2025Headnote And Keywords-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 30, 2024Zustellnachweis-
Sep 30, 2024Notification Of Service-
Sep 25, 2024Acknowledgement Of Access To Case-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Document From Epo-
Sep 4, 2024Panel Appointment-
Sep 4, 2024Letter For Service-
Sep 4, 2024Formal Checks Notification Of Positive Outcome-
Sep 4, 2024Epo Request For Case Pending-
Sep 4, 2024Acknowledgement Of Lodging-
Sep 2, 2024Tw D8 De Leaflet Cabazitaxel-
Sep 2, 2024Tw D7 De Smpc Cabazitaxel-
Sep 2, 2024Tw D6 Fr Leaflet Cabazitaxel-
Sep 2, 2024Tw D5 Fr Smpc Cabazitaxel-
Sep 2, 2024Tw D4 Ansm Cabazitaxel-
Sep 2, 2024Tw D3 Report Eu Commission-
Sep 2, 2024Tw D2 Medicines For Europe-
Sep 2, 2024Dfmp P7 Priority Document US61 389,969-
Sep 2, 2024Dfmp P6 Priority Document US61 383933-
Sep 2, 2024Dfmp P5 Priority Document US61 369929-
Sep 2, 2024Dfmp P4 Priority Document US61 355888-
Sep 2, 2024Dfmp P3 Priority Document US61 355834-
Sep 2, 2024Dfmp P2 Priority Document US61 293903-
Sep 2, 2024Dfmp P1 Priority Document US61 256160-
Sep 2, 2024Dfmp D9 Galletti Et Al.-
Sep 2, 2024Dfmp D91 Bissery Et Al.-
Sep 2, 2024Dfmp D90 Goetz Et Al.-
Sep 2, 2024Dfmp D7 Beardsley Et Al.-
Sep 2, 2024Dfmp D72 Scher Et Al.-
Sep 2, 2024Dfmp D4 Mita Et Al.-
Sep 2, 2024Dfmp D3B Further Blog Post By Dr. Mirtsching July 6-
Sep 2, 2024Dfmp D3A Blog Post By Dr. Barry Mirtsching 12 October-
Sep 2, 2024Dfmp D38 Sanofi Press Release September 17-
Sep 2, 2024Dfmp D37 Winquist Et Al.-
Sep 2, 2024Dfmp D35 Leaflet Aventis Oncology-
Sep 2, 2024Dfmp D2 National Horizon Scanning Centre-
Sep 2, 2024Dfmp D29 Tannock Et Al.-
Sep 2, 2024Dfmp D26 Attard Et Al.-
Sep 2, 2024Dfmp D25 Correspondence Lancet 2011 377 121 122-
Sep 2, 2024Dfmp D21 Ema Assessment Report For Jevtana (Cabazitaxel) January 20-
Sep 2, 2024Dfmp D1 Sanofi Aventis Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone-
Sep 2, 2024Dfmp D18 Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man-
Sep 2, 2024Dfmp D15 De Bono Et Al.-
Sep 2, 2024Dfmp D14 Fda Label For Docetaxel (Taxotere)-
Sep 2, 2024Dfmp D13 Pivot Et Al.-
Sep 2, 2024Dfmp D11 Les Echos 22 Dec-
Sep 2, 2024Dfmp D113 Us Code Of Federal Regulations Title 21 Chapter I Part 314-
Sep 2, 2024Dfmp D112 Excerpt From The Online National Cancer Institute S Drug Dictionary Re. Cabazitaxel-
Sep 2, 2024Dfmp D111 Inn Publication-
Sep 2, 2024Dfmp D110 Consolidated List Of Documents Epo-
Sep 2, 2024Dfmp D10 Sanofi Aventis Press Release 21 December-
Sep 2, 2024Dfmp D109 Albarqouni-
Sep 2, 2024Dfmp D108 Barraclough And Davis-
Sep 2, 2024Dfmp D105 Sava Et Al.-
Sep 2, 2024Dfmp D104 Tannock Clin. Oncol. 1996-
Sep 2, 2024Dfmp D103 Fossa. Et Al.-
Sep 2, 2024Dfmp D102 Tannock Clin. Oncol. 1989-
Sep 2, 202409 02 Sanofi VS. Zentiva Statement Of Defence And Counterclaim For Revoc-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 10, 2025Acknowledgement Of Change Of A Representative-
Jul 8, 2025Formal Checks Notification Of Positive Outcome-
Jul 8, 2025Exhibit Tw D 17 Signed-
Jul 8, 2025Exhibit Tw D 16 Signed-
Jul 8, 2025Exhibit Tw D 15 Signed-
Jul 8, 2025Exhibit Tw D 14 Signed-
Jul 8, 2025Exhibit Dfmp D115 Signed-
Jul 8, 2025Exhibit Dfmp D114 Signed-
Jul 8, 2025Application Rop293 Receipt-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Sanovi VS. Zentiva Zentiva Rejoinder Infringement Reply Counterclaim Signed-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
May 8, 2025Outcome Of The Order-
May 8, 2025Final Order
Apr 11, 2025Receipt-
Apr 9, 2025Exhibit Tw D9 Signed-
Apr 9, 2025Exhibit Tw D12B 373 740 Signed-
Apr 9, 2025Exhibit Tw D12A 1 372 Signed-
Apr 9, 2025Exhibit Tw D11 Signed-
Apr 9, 2025Exhibit Tw D10 Signed-
Apr 9, 202504 09 Sanofi V Zentiva Zentiva Reply To Sanofi Comments No 2 R. 105 Signed-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 24, 2025Headnote And Keywords-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 30, 2024Zustellnachweis-
Sep 30, 2024Notification Of Service-
Sep 25, 2024Acknowledgement Of Access To Case-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Document From Epo-
Sep 4, 2024Panel Appointment-
Sep 4, 2024Letter For Service-
Sep 4, 2024Formal Checks Notification Of Positive Outcome-
Sep 4, 2024Epo Request For Case Pending-
Sep 4, 2024Acknowledgement Of Lodging-
Sep 2, 2024Tw D8 De Leaflet Cabazitaxel-
Sep 2, 2024Tw D7 De Smpc Cabazitaxel-
Sep 2, 2024Tw D6 Fr Leaflet Cabazitaxel-
Sep 2, 2024Tw D5 Fr Smpc Cabazitaxel-
Sep 2, 2024Tw D4 Ansm Cabazitaxel-
Sep 2, 2024Tw D3 Report Eu Commission-
Sep 2, 2024Tw D2 Medicines For Europe-
Sep 2, 2024Dfmp P7 Priority Document US61 389,969-
Sep 2, 2024Dfmp P6 Priority Document US61 383933-
Sep 2, 2024Dfmp P5 Priority Document US61 369929-
Sep 2, 2024Dfmp P4 Priority Document US61 355888-
Sep 2, 2024Dfmp P3 Priority Document US61 355834-
Sep 2, 2024Dfmp P2 Priority Document US61 293903-
Sep 2, 2024Dfmp P1 Priority Document US61 256160-
Sep 2, 2024Dfmp D9 Galletti Et Al.-
Sep 2, 2024Dfmp D91 Bissery Et Al.-
Sep 2, 2024Dfmp D90 Goetz Et Al.-
Sep 2, 2024Dfmp D7 Beardsley Et Al.-
Sep 2, 2024Dfmp D72 Scher Et Al.-
Sep 2, 2024Dfmp D4 Mita Et Al.-
Sep 2, 2024Dfmp D3B Further Blog Post By Dr. Mirtsching July 6-
Sep 2, 2024Dfmp D3A Blog Post By Dr. Barry Mirtsching 12 October-
Sep 2, 2024Dfmp D38 Sanofi Press Release September 17-
Sep 2, 2024Dfmp D37 Winquist Et Al.-
Sep 2, 2024Dfmp D35 Leaflet Aventis Oncology-
Sep 2, 2024Dfmp D2 National Horizon Scanning Centre-
Sep 2, 2024Dfmp D29 Tannock Et Al.-
Sep 2, 2024Dfmp D26 Attard Et Al.-
Sep 2, 2024Dfmp D25 Correspondence Lancet 2011 377 121 122-
Sep 2, 2024Dfmp D21 Ema Assessment Report For Jevtana (Cabazitaxel) January 20-
Sep 2, 2024Dfmp D1 Sanofi Aventis Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone-
Sep 2, 2024Dfmp D18 Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man-
Sep 2, 2024Dfmp D15 De Bono Et Al.-
Sep 2, 2024Dfmp D14 Fda Label For Docetaxel (Taxotere)-
Sep 2, 2024Dfmp D13 Pivot Et Al.-
Sep 2, 2024Dfmp D11 Les Echos 22 Dec-
Sep 2, 2024Dfmp D113 Us Code Of Federal Regulations Title 21 Chapter I Part 314-
Sep 2, 2024Dfmp D112 Excerpt From The Online National Cancer Institute S Drug Dictionary Re. Cabazitaxel-
Sep 2, 2024Dfmp D111 Inn Publication-
Sep 2, 2024Dfmp D110 Consolidated List Of Documents Epo-
Sep 2, 2024Dfmp D10 Sanofi Aventis Press Release 21 December-
Sep 2, 2024Dfmp D109 Albarqouni-
Sep 2, 2024Dfmp D108 Barraclough And Davis-
Sep 2, 2024Dfmp D105 Sava Et Al.-
Sep 2, 2024Dfmp D104 Tannock Clin. Oncol. 1996-
Sep 2, 2024Dfmp D103 Fossa. Et Al.-
Sep 2, 2024Dfmp D102 Tannock Clin. Oncol. 1989-
Sep 2, 202409 02 Sanofi VS. Zentiva Statement Of Defence And Counterclaim For Revoc-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 10, 2025Acknowledgement Of Change Of A Representative-
Jul 8, 2025Formal Checks Notification Of Positive Outcome-
Jul 8, 2025Exhibit Tw D 17 Signed-
Jul 8, 2025Exhibit Tw D 16 Signed-
Jul 8, 2025Exhibit Tw D 15 Signed-
Jul 8, 2025Exhibit Tw D 14 Signed-
Jul 8, 2025Exhibit Dfmp D115 Signed-
Jul 8, 2025Exhibit Dfmp D114 Signed-
Jul 8, 2025Application Rop293 Receipt-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Sanovi VS. Zentiva Zentiva Rejoinder Infringement Reply Counterclaim Signed-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
May 8, 2025Outcome Of The Order-
May 8, 2025Final Order
Apr 11, 2025Receipt-
Apr 9, 2025Exhibit Tw D9 Signed-
Apr 9, 2025Exhibit Tw D12B 373 740 Signed-
Apr 9, 2025Exhibit Tw D12A 1 372 Signed-
Apr 9, 2025Exhibit Tw D11 Signed-
Apr 9, 2025Exhibit Tw D10 Signed-
Apr 9, 202504 09 Sanofi V Zentiva Zentiva Reply To Sanofi Comments No 2 R. 105 Signed-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 24, 2025Headnote And Keywords-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 30, 2024Zustellnachweis-
Sep 30, 2024Notification Of Service-
Sep 25, 2024Acknowledgement Of Access To Case-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Document From Epo-
Sep 4, 2024Panel Appointment-
Sep 4, 2024Letter For Service-
Sep 4, 2024Formal Checks Notification Of Positive Outcome-
Sep 4, 2024Epo Request For Case Pending-
Sep 4, 2024Acknowledgement Of Lodging-
Sep 2, 2024Tw D8 De Leaflet Cabazitaxel-
Sep 2, 2024Tw D7 De Smpc Cabazitaxel-
Sep 2, 2024Tw D6 Fr Leaflet Cabazitaxel-
Sep 2, 2024Tw D5 Fr Smpc Cabazitaxel-
Sep 2, 2024Tw D4 Ansm Cabazitaxel-
Sep 2, 2024Tw D3 Report Eu Commission-
Sep 2, 2024Tw D2 Medicines For Europe-
Sep 2, 2024Dfmp P7 Priority Document US61 389,969-
Sep 2, 2024Dfmp P6 Priority Document US61 383933-
Sep 2, 2024Dfmp P5 Priority Document US61 369929-
Sep 2, 2024Dfmp P4 Priority Document US61 355888-
Sep 2, 2024Dfmp P3 Priority Document US61 355834-
Sep 2, 2024Dfmp P2 Priority Document US61 293903-
Sep 2, 2024Dfmp P1 Priority Document US61 256160-
Sep 2, 2024Dfmp D9 Galletti Et Al.-
Sep 2, 2024Dfmp D91 Bissery Et Al.-
Sep 2, 2024Dfmp D90 Goetz Et Al.-
Sep 2, 2024Dfmp D7 Beardsley Et Al.-
Sep 2, 2024Dfmp D72 Scher Et Al.-
Sep 2, 2024Dfmp D4 Mita Et Al.-
Sep 2, 2024Dfmp D3B Further Blog Post By Dr. Mirtsching July 6-
Sep 2, 2024Dfmp D3A Blog Post By Dr. Barry Mirtsching 12 October-
Sep 2, 2024Dfmp D38 Sanofi Press Release September 17-
Sep 2, 2024Dfmp D37 Winquist Et Al.-
Sep 2, 2024Dfmp D35 Leaflet Aventis Oncology-
Sep 2, 2024Dfmp D2 National Horizon Scanning Centre-
Sep 2, 2024Dfmp D29 Tannock Et Al.-
Sep 2, 2024Dfmp D26 Attard Et Al.-
Sep 2, 2024Dfmp D25 Correspondence Lancet 2011 377 121 122-
Sep 2, 2024Dfmp D21 Ema Assessment Report For Jevtana (Cabazitaxel) January 20-
Sep 2, 2024Dfmp D1 Sanofi Aventis Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone-
Sep 2, 2024Dfmp D18 Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man-
Sep 2, 2024Dfmp D15 De Bono Et Al.-
Sep 2, 2024Dfmp D14 Fda Label For Docetaxel (Taxotere)-
Sep 2, 2024Dfmp D13 Pivot Et Al.-
Sep 2, 2024Dfmp D11 Les Echos 22 Dec-
Sep 2, 2024Dfmp D113 Us Code Of Federal Regulations Title 21 Chapter I Part 314-
Sep 2, 2024Dfmp D112 Excerpt From The Online National Cancer Institute S Drug Dictionary Re. Cabazitaxel-
Sep 2, 2024Dfmp D111 Inn Publication-
Sep 2, 2024Dfmp D110 Consolidated List Of Documents Epo-
Sep 2, 2024Dfmp D10 Sanofi Aventis Press Release 21 December-
Sep 2, 2024Dfmp D109 Albarqouni-
Sep 2, 2024Dfmp D108 Barraclough And Davis-
Sep 2, 2024Dfmp D105 Sava Et Al.-
Sep 2, 2024Dfmp D104 Tannock Clin. Oncol. 1996-
Sep 2, 2024Dfmp D103 Fossa. Et Al.-
Sep 2, 2024Dfmp D102 Tannock Clin. Oncol. 1989-
Sep 2, 202409 02 Sanofi VS. Zentiva Statement Of Defence And Counterclaim For Revoc-
Oct 8, 2025Receipt-
Oct 8, 2025Further Pleadings-
Oct 8, 2025Exhibit-
Oct 8, 2025Cover Sheet-
Sep 15, 2025Oral Hearing Reference Ic-
Sep 10, 2025Written Procedure Closure-
Sep 10, 2025Interim Conference Decision-
Sep 10, 2025Fix Interim Conference Date-
Aug 8, 2025Rejoinder-
Aug 8, 2025Exhibit No. B.22-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B.2.2-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. B-
Aug 8, 2025Exhibit No. 0-
Aug 8, 2025Acknowledgement Of Lodging-
Jul 10, 2025Acknowledgement Of Change Of A Representative-
Jul 8, 2025Formal Checks Notification Of Positive Outcome-
Jul 8, 2025Exhibit Tw D 17 Signed-
Jul 8, 2025Exhibit Tw D 16 Signed-
Jul 8, 2025Exhibit Tw D 15 Signed-
Jul 8, 2025Exhibit Tw D 14 Signed-
Jul 8, 2025Exhibit Dfmp D115 Signed-
Jul 8, 2025Exhibit Dfmp D114 Signed-
Jul 8, 2025Application Rop293 Receipt-
Jul 8, 2025Acknowledgement Of Lodging-
Jul 8, 202507 08 Sanovi VS. Zentiva Zentiva Rejoinder Infringement Reply Counterclaim Signed-
Jun 27, 2025Application Rop293-
Jun 27, 2025Application-
May 8, 2025Outcome Of The Order-
May 8, 2025Final Order
Apr 11, 2025Receipt-
Apr 9, 2025Exhibit Tw D9 Signed-
Apr 9, 2025Exhibit Tw D12B 373 740 Signed-
Apr 9, 2025Exhibit Tw D12A 1 372 Signed-
Apr 9, 2025Exhibit Tw D11 Signed-
Apr 9, 2025Exhibit Tw D10 Signed-
Apr 9, 202504 09 Sanofi V Zentiva Zentiva Reply To Sanofi Comments No 2 R. 105 Signed-
Jan 24, 2025Scheduling Ic And Oh For Cc
Jan 24, 2025Hearing Dates-
Jan 24, 2025Headnote And Keywords-
Jan 17, 2025R 305 Second Final
Jan 17, 2025Outcome Of The Order-
Jan 16, 2025Hearing Reference-
Jan 13, 2025R 305 Second Oral Comments-
Jan 13, 2025Hearing Dates-
Jan 9, 2025Receipt-
Jan 9, 2025Exhibit No. A.02-
Jan 9, 2025Application-
Nov 1, 2024Reply And Defence-
Nov 1, 2024Formal Checks Notification Of Positive Outcome-
Nov 1, 2024Acknowledgement Of Lodging-
Sep 30, 2024Zustellnachweis-
Sep 30, 2024Notification Of Service-
Sep 25, 2024Acknowledgement Of Access To Case-
Sep 17, 2024Epouploaddocumentsworkflow-
Sep 16, 2024Document From Epo-
Sep 4, 2024Panel Appointment-
Sep 4, 2024Letter For Service-
Sep 4, 2024Formal Checks Notification Of Positive Outcome-
Sep 4, 2024Epo Request For Case Pending-
Sep 4, 2024Acknowledgement Of Lodging-
Sep 2, 2024Tw D8 De Leaflet Cabazitaxel-
Sep 2, 2024Tw D7 De Smpc Cabazitaxel-
Sep 2, 2024Tw D6 Fr Leaflet Cabazitaxel-
Sep 2, 2024Tw D5 Fr Smpc Cabazitaxel-
Sep 2, 2024Tw D4 Ansm Cabazitaxel-
Sep 2, 2024Tw D3 Report Eu Commission-
Sep 2, 2024Tw D2 Medicines For Europe-
Sep 2, 2024Dfmp P7 Priority Document US61 389,969-
Sep 2, 2024Dfmp P6 Priority Document US61 383933-
Sep 2, 2024Dfmp P5 Priority Document US61 369929-
Sep 2, 2024Dfmp P4 Priority Document US61 355888-
Sep 2, 2024Dfmp P3 Priority Document US61 355834-
Sep 2, 2024Dfmp P2 Priority Document US61 293903-
Sep 2, 2024Dfmp P1 Priority Document US61 256160-
Sep 2, 2024Dfmp D9 Galletti Et Al.-
Sep 2, 2024Dfmp D91 Bissery Et Al.-
Sep 2, 2024Dfmp D90 Goetz Et Al.-
Sep 2, 2024Dfmp D7 Beardsley Et Al.-
Sep 2, 2024Dfmp D72 Scher Et Al.-
Sep 2, 2024Dfmp D4 Mita Et Al.-
Sep 2, 2024Dfmp D3B Further Blog Post By Dr. Mirtsching July 6-
Sep 2, 2024Dfmp D3A Blog Post By Dr. Barry Mirtsching 12 October-
Sep 2, 2024Dfmp D38 Sanofi Press Release September 17-
Sep 2, 2024Dfmp D37 Winquist Et Al.-
Sep 2, 2024Dfmp D35 Leaflet Aventis Oncology-
Sep 2, 2024Dfmp D2 National Horizon Scanning Centre-
Sep 2, 2024Dfmp D29 Tannock Et Al.-
Sep 2, 2024Dfmp D26 Attard Et Al.-
Sep 2, 2024Dfmp D25 Correspondence Lancet 2011 377 121 122-
Sep 2, 2024Dfmp D21 Ema Assessment Report For Jevtana (Cabazitaxel) January 20-
Sep 2, 2024Dfmp D1 Sanofi Aventis Xrp6258 Plus Prednisone Compared To Mitoxantrone Plus Prednisone-
Sep 2, 2024Dfmp D18 Ema Guideline On The Evaluation Of Anticancer Medicinal Products In Man-
Sep 2, 2024Dfmp D15 De Bono Et Al.-
Sep 2, 2024Dfmp D14 Fda Label For Docetaxel (Taxotere)-
Sep 2, 2024Dfmp D13 Pivot Et Al.-
Sep 2, 2024Dfmp D11 Les Echos 22 Dec-
Sep 2, 2024Dfmp D113 Us Code Of Federal Regulations Title 21 Chapter I Part 314-
Sep 2, 2024Dfmp D112 Excerpt From The Online National Cancer Institute S Drug Dictionary Re. Cabazitaxel-
Sep 2, 2024Dfmp D111 Inn Publication-
Sep 2, 2024Dfmp D110 Consolidated List Of Documents Epo-
Sep 2, 2024Dfmp D10 Sanofi Aventis Press Release 21 December-
Sep 2, 2024Dfmp D109 Albarqouni-
Sep 2, 2024Dfmp D108 Barraclough And Davis-
Sep 2, 2024Dfmp D105 Sava Et Al.-
Sep 2, 2024Dfmp D104 Tannock Clin. Oncol. 1996-
Sep 2, 2024Dfmp D103 Fossa. Et Al.-
Sep 2, 2024Dfmp D102 Tannock Clin. Oncol. 1989-
Sep 2, 202409 02 Sanofi VS. Zentiva Statement Of Defence And Counterclaim For Revoc-

More cases involving EP2493466B1

This table lists the related cases associated with the patent, including case numbers, plaintiffs, and defendants involved in each case.

Last updated on: Oct 9, 2025
Case NumberFiling DatePlaintiffsDefendants
CC_48036/2024Sep 2, 2024Stada Arzneimittel, Stada Nordic, StadapharmSanofi, Sanofi Aventis, Sanofi Aventis Deutschland, Sanofi Aventis France, Sanofi Belgium, Sanofi Mature, Sanofi Produtos Farmaceuticos LDA, Sanofi Winthrop Industrie
CC_49716/2024Sep 2, 2024Zentiva, Zentiva France, Zentiva PharmaSanofi Mature
UPC_CFI_496/2024Sep 2, 2024Stada Arzneimittel, Stada Nordic, StadapharmSanofi, Sanofi AB, Sanofi Aventis, Sanofi Aventis Deutschland, Sanofi Aventis France, Sanofi Belgium, Sanofi Mature, Sanofi Produtos Farmaceuticos LDA, Sanofi Winthrop Industrie

More cases involving Zentiva

This table lists the related cases associated with the patent, including case numbers, plaintiffs, and defendants involved in each case.

Last updated on: Oct 9, 2025
Case NumberFiling DatePlaintiffsDefendants
App_34541/2025Aug 11, 2025Zentiva, Zentiva France, Zentiva Pharma -
App_24524/2025May 23, 2025Zentiva, Zentiva France, Zentiva Pharma -
App_9038/2025Feb 28, 2025Zentiva KS, Zentiva Portugal -

More cases involving Sanofi Mature

This table lists the related cases associated with the patent, including case numbers, plaintiffs, and defendants involved in each case.

Last updated on: Oct 9, 2025
Case NumberFiling DatePlaintiffsDefendants
ORD_33148/2025Jul 17, 2025Sanofi MatureStada Arzneimittel, Stada Nordic, Stadapharm
App_32509/2025Jul 8, 2025Betapharm Arzneimittel, DR Reddys, Reddy PharmaSanofi Mature
App_32523/2025Jul 8, 2025Betapharm Arzneimittel, DR Reddys, Reddy PharmaSanofi Mature